Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Candel Therapeutics ( (CADL) ) has issued an announcement.
On August 18, 2025, Candel Therapeutics Inc. extended its lease agreement for its premises in Needham, Massachusetts, from August 31, 2026, to August 31, 2029. The lease amendment includes a base rent of $607,880 per year starting September 1, 2026, with an annual increase of $15,197, impacting the company’s operational costs and long-term planning.
The most recent analyst rating on (CADL) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.
Spark’s Take on CADL Stock
According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.
Candel Therapeutics is currently facing substantial financial challenges with no revenue and ongoing cash burn, which heavily weighs down its stock score. Despite positive clinical trial results offering future potential, the current technical and valuation metrics remain unfavorable, reflecting the speculative nature of the stock.
To see Spark’s full report on CADL stock, click here.
More about Candel Therapeutics
Candel Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing oncolytic viral immunotherapies for cancer treatment.
Average Trading Volume: 904,901
Technical Sentiment Signal: Buy
Current Market Cap: $305.2M
Learn more about CADL stock on TipRanks’ Stock Analysis page.